Anticancer agent 231,128519-30

Anticancer agent 231 产品活性：Anticancer agent 231 (化合物 P5) 是一种酪氨酸蛋白激酶抑制剂，IC50 值为 3.95 μM。Anticancer agent 231 通过靶向 EGFR-ERK1/2 信号通路抑制三阴乳腺癌 (TNBC) 细胞的细胞活力、细胞增殖、细胞迁移和癌症干性，有望在 TNBC 疾病治疗领域发挥重要作用。 产品来源： www.medchemexpress.cn/anticancer-agent-231.html 研究领域：MAPK/ERK Pathway | Stem Cell/Wnt 作用靶点：ERK In Vitro: Anticancer agent 231 (Compound P5) has good cytotoxicity and inhibits TNBC cells’ viability. Anticancer agent 231 (Compound P5) (1, 2, 4 μM, 14 days; 1, 2, 4 μM, 8 days) decreases the proliferation capacity of Hs578T cells and MDA MB-231 cells. Anticancer agent 231 (Compound P5) (1, 2, 4 μM, 12 h) decreases the migration ability of Hs578T cells. Anticancer agent 231 (Compound P5) (1, 2 μM) inhibits tumor stemness and enhances the sensitivity of TNBC cells to paclitaxel. Anticancer agent 231 (Compound P5) (1, 2, 4 μM; 5, 10, 20 μM) inhibits TNBC cells by targeting the EGFR-ERK 1/2 axis. 相关产品：PD98059 | Yoda 1 | SCH772984 | TBHQ | Tauroursodeoxycholate | β-Glycerophosphate disodium salt pentahydrate | Honokiol | Ulixertinib | Astragaloside IV | Piperlongumine | Temuterkib | Ravoxertinib | C16-PAF | Lidocaine | Patritumab | Fucoxanthin | RMC-6291 | FR 180204 | Salbutamol | 6-OAU | trans-Zeatin | ASN007 | BIX02189 | Pamoic acid | Lysophosphatidylcholines | XMD8-92 | MK-8353 | Urolithin B 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种TOP期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪前沿的制药及生命科学研究进展，为您提供全球前沿的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。